Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas

Surgery (United States)

Volumn 159, Issue 1, 2016, Pages 284-295

  Subramanian, Chitra ^a   Kuai, Rui ^a   Zhu, Qing ^a   White, Peter ^a   Moon, James J ^a   Schwendeman, Anna ^a   Cohen, Mark S ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALDOSTERONE SYNTHASE; AROMATASE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CISPLATIN; CYTOCHROME P450 11B1; CYTOCHROME P450 17 A1; CYTOCHROME P450 21 A2; ETOPOSIDE; HYDROCORTISONE; MESSENGER RNA; MITOTANE; NANOPARTICLE; SCAVENGER RECEPTOR BI; SYNTHETIC HIGH DENSITY LIPOPROTEIN NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HIGH DENSITY LIPOPROTEIN; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B;

ADRENAL CORTEX CARCINOMA; ADRENOCORTICAL CARCINOMA CELL LINE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CELL VIABILITY; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HYDROCORTISONE BLOOD LEVEL; MITOCHONDRIAL MEMBRANE POTENTIAL; NANOMEDICINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STEROIDOGENESIS; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG THERAPY, COMBINATION; HUMANS; HYDROCORTISONE; LIPOPROTEINS, HDL; NANOPARTICLES; SCAVENGER RECEPTORS, CLASS B;

EID: 84952637828     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2015.08.023     Document Type: Conference Paper

References (25)

1. A. Stigliano, L. Cerquetti, C. Sampaoli, B. Bucci, and V. Toscano Current and emerging therapeutic options in adrenocortical cancer treatment J Oncol 2012 2012 408131 PubMed PMID: 22934112. Pubmed Central PMCID: 3425859
2. P. Icard, Y. Chapuis, B. Andreassian, A. Bernard, and C. Proye Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery Surgery 112 1992 972 979 discussion 9-80. PubMed PMID: 1455322
3. S. De Francia, A. Ardito, F. Daffara, B. Zaggia, A. Germano, A. Berruti, and et al. Mitotane treatment for adrenocortical carcinoma: an overview Minerv Endocrinol 37 2012 9 23 PubMed PMID: 22382612.
4. M. Fassnacht, M. Kroiss, and B. Allolio Update in adrenocortical carcinoma J Clin Endocrinol Metab 98 2013 4551 4564 PubMed PMID: 24081734
5. A. Germano, I. Rapa, M. Volante, N. Lo Buono, S. Carturan, A. Berruti, and et al. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines Mol Cell Endocrinol 382 2014 1 7 PubMed PMID: 24018612
6. A. Berruti, E. Baudin, H. Gelderblom, H.R. Haak, F. Porpiglia, M. Fassnacht, and et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl 7 2012 vii131 vii138 PubMed PMID: 22997446
7. I. Bourdeau, J. MacKenzie-Feder, and A. Lacroix Recent advances in adrenocortical carcinoma in adults Curr Opin Endocrinol Diabetes Obes 20 2013 192 197 PubMed PMID: 23549307
8. A.R. Glover, J.C. Ip, J.T. Zhao, P.S. Soon, B.G. Robinson, and S.B. Sidhu Current management options for recurrent adrenocortical carcinoma OncoTargets Ther 6 2013 635 643 PubMed PMID: 23776337. Pubmed Central PMCID: 3681406
9. W.L. Miller, and R.J. Auchus The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders Endocr Rev 32 2011 81 151 PubMed PMID: 21051590. Pubmed Central PMCID: 3365799
10. P.G. Yancey, M. de la Llera-Moya, S. Swarnakar, P. Monzo, S.M. Klein, M.A. Connelly, and et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI J Biol Chem 275 2000 36596 36604 PubMed PMID: 10964930
11. S. Yang, M.G. Damiano, H. Zhang, S. Tripathy, A.J. Luthi, J.S. Rink, and et al. Biomimetic, synthetic HDL nanostructures for lymphoma Proc Natl Acad Sci U S A 110 2013 2511 2516 PubMed PMID: 23345442. Pubmed Central PMCID: 3574906
12. Y. Zheng, Y. Liu, H. Jin, S. Pan, Y. Qian, C. Huang, and et al. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles Theranostics 3 2013 477 486 PubMed PMID: 23843895. Pubmed Central PMCID: 3706691
13. B.R. Krause, and A.T. Remaley Reconstituted HDL for the acute treatment of acute coronary syndrome Curr Opin Lipidol 24 2013 480 486 PubMed PMID: 24184938
14. A.M. Lerario, A. Moraitis, and G.D. Hammer Genetics and epigenetics of adrenocortical tumors Mol Cell Endocrinol 386 2014 67 84 PubMed PMID: 24220673. Pubmed Central PMCID: 3943605
15. W.E. Rainey, J.W. Shay, and J.I. Mason ACTH induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase, cholesterol biosynthesis, and steroidogenesis in primary cultures of bovine adrenocortical cells J Biol Chem 261 1986 7322 7326 PubMed PMID: 3011782
16. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55 PubMed PMID: 6382953
17. C. Subramanian, H. Zhang, R. Gallagher, G. Hammer, B. Timmermann, and M. Cohen Withanolides are potent novel targeted therapeutic agents against adrenocortical carcinomas World J Surg 38 2014 1343 1352 PubMed PMID: 24763440
18. A. Oskarsson, E. Ulleras, K.E. Plant, J.P. Hinson, and P.S. Goldfarb Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro J Appl Toxicol 26 2006 484 492 PubMed PMID: 17080404
19. M. Jain, L. Zhang, M. He, Y.Q. Zhang, M. Shen, and E. Kebebew TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma Endocr Relat Cancer 20 2013 361 370 PubMed PMID: 23533247
20. Rasband WS. Image J, U.S. National Institute of Health, Bethesda (MD). http://imagej.nih.gov/ij/, 1997-2004.
21. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res 70 2010 440 446 PubMed PMID: 20068163
22. T. Else, A.C. Kim, A. Sabolch, V.M. Raymond, A. Kandathil, E.M. Caoili, and et al. Adrenocortical carcinoma Endocr Rev 35 2014 282 326 PubMed PMID: 24423978. Pubmed Central PMCID: 3963263
23. N.P. van Erp, H.J. Guchelaar, B.A. Ploeger, J.A. Romijn, J. Hartigh, and H. Gelderblom Mitotane has a strong and a durable inducing effect on CYP3A4 activity Eur J Endocrinol 164 2011 621 626 PubMed PMID: 21220434
24. J.T. Gwynne, and J.F. Strauss 3rd The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands Endocrine Rev 3 1982 299 329 PubMed PMID: 6288367
25. D.R. Illingworth, and E.S. Orwoll Low-density lipoproteins and adrenal cortisol production: studies in abetalipoproteinaemia and hypobetalipoproteinaemia Biochem Soc Transact 9 1981 50 PubMed PMID: 6260556